Discovery of small molecule inhibitors targeting oncogenic CHD1L with preclinical activity in colorectal cancer
The majority of colorectal cancers arise from dysregulation in the Wnt signaling pathway. Aberrant Wnt signaling is associated with tumor formation, metastasis, and drug resistance. Many current therapeutic strategies attempt to target downstream effectors of the Wnt pathway, most notably protein-protein interactions that mediate formation of b-catenin/TCF4 complexes. These strategies have had limited clinical success, due in part to there being a limited amount of known druggable targets involved with activating transcription of Wnt target genes. In an attempt to develop more effective therapies ...
(For more, see "View full record.")
LaBarbera, Daniel V.
Embargo Expires: 06/22/2022